Loading clinical trials...

Telehealth-based Symptom Management for Veterans Treated With Selinexor | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Telehealth-based Symptom Management for Veterans Treated With Selinexor

NCT06452446•Durham VA Medical Center

Summary

The purpose of this study is to find out if continued monitoring of side effects from Selinexor and prescribed medication to prevent side effects helps improve symptoms, quality of life, and ability to continue the treatment longer.

Detailed Description

The primary objective of this study is to evaluate control of treatment-related and cancer-associated symptoms over the first three months of therapy with selinexor in Veterans who participate in a telehealth symptom management intervention. The secondary objectives are: * To describe characteristics of patients treated with selinexor. * To describe adherence with the telehealth intervention. * To define the type and frequency of adverse events that patients experience while taking selinexor. * To describe the duration of selinexor therapy and evaluate adherence and dose intensity of selinexor in VA cancer patients receiving a telehealth symptom management intervention. * To describe concomitant medication usage in patients treated with selinexor. * To assess quality of life in patients treated with selinexor in the VA. * To estimate progression-free survival in VA cancer patients treated with selinexor.

Eligibility

Age

18 - 89 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of B-cell malignancy: either relapsed or refractory multiple myeloma or diffuse large B-cell lymphoma, meeting the FDA-approved indication for Selinexor treatment.
•Requiring therapy as assessed by the treating oncology provider.
•Prior authorization drug request for selinexor approved by VA oncology pharmacist.
•Subject age 18 years or older.
•Subject willing and able to perform video or telephone research visits.
•Subjects must be able to read and comprehend English.
•Subject must be a Veteran receiving cancer care from a VA facility affiliated with the National Teleoncology Program.
•Patients must be enrolled prior to starting Selinexor.

Exclusion Criteria

•Any prior or current therapy with selinexor.
•Any medical, psychiatric, or cognitive issue that the principal investigator or the subject's oncologists believes would prevent participation or completion of the study.
•Individuals who are vulnerable to coercion or undue influence.
•Any individuals or populations that may temporarily or permanently require additional considerations include such as those susceptible to coercion or undue influence (e.g., patients with limited or no treatment options, socially and economically disadvantaged persons).
•Current selinexor therapy that is part of an investigational clinical trial.

Locations (1)

Durham VA Medical Center

Durham, North Carolina, United States

Key Dates

Start Date

September 1, 2024

Primary Completion Date

July 1, 2026

Completion Date

July 1, 2028

Last Updated

February 10, 2025

Enrollment

ESTIMATED participants

Conditions

Multiple MyelomaLarge-cell Lymphoma

Interventions

Selinexor

DRUG

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT06179888

Multiple Myeloma

View study

RECRUITINGPHASE3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575

Multiple Myeloma

View study

RECRUITINGPHASE1/PHASE2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Telehealth-based Symptom Management for Veterans Treated With Selinexor

Inclusion Criteria

Exclusion Criteria

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Elranatamab in R/R Multiple Myeloma

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)